Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study
, , and | May 28, 2020
About this article
Article Category: Research Article
Published Online: May 28, 2020
Page range: 233 - 236
Received: Nov 18, 2019
Accepted: Dec 01, 2019
DOI: https://doi.org/10.2478/raon-2020-0027
© 2020 Jurij Hanzel, Tajda Kosir Bozic, Borut Stabuc, Rado Jansa, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Patient characteristics at initiation of sorafenib (n = 115)
| Variable | |
|---|---|
| Male gender, n (%) | 96 (84) |
| Age, years, median (IQR) | 67 (60–72) |
| ECOG performance status | |
| 0 | 31 (27) |
| 1 | 47 (40.9) |
| 2 | 36 (31.3) |
| 3 | 1 (0.9) |
| Aetiology of underlying liver disease, n (%) | |
| Alcoholic liver disease | 56 (49) |
| Hepatitis B | 11 (9.6) |
| Hepatitis C | 7 (6.1) |
| Non-alcoholic steatohepatitis | 18 (15.7) |
| Cryptogenic | 10 (8.7) |
| Wilson’s disease | 1 (0.9) |
| Primary biliary cholangitis | 1 (0.9) |
| HCC in non-cirrhotic liver | 11 (9.6) |
| Child-Pugh class, n (%) | |
| A | 77 (66.9) |
| B | 37 (32.2) |
| C | 1 (0.9) |
| BCLC stage, n (%) | |
| A | 3 (2.6) |
| B | 42 (36.5) |
| C | 70 (60.9) |
| Prior treatment, n (%) | 45 (39.1) |
| Resection | 10 (8.7) |
| RFA | 2 (1.8) |
| Transplant | 3 (2.6) |
| TACE | 29 (25.2) |
| Radioembolization | 5 (4.3) |
| AFP, kU/L, median (IQR) | 6–1518) |
Factors associated with overall survival (OS) after initiation of sorafenib
| Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
| Median survival in months (95% CI) | Log rank | Hazard ratio (95% CI) | Cox’s regression | |
| ECOG performance status | ||||
| 0 | 25.1 (12.8–37.4) | |||
| 1 | 17.0 (7.0–26.9) | <0.0001 | 2.21 (1.56–3.16) | <0.0001 |
| 2 | 5.5 (3.7–7.3) | |||
| 3 | 7.3 (/) | |||
| Child-Pugh class | ||||
| A | 16.9 (12.8–21.0) | |||
| B | 6.7 (4.7–8.7) | <0.0001 | 1.00 1.34 (0.80–2.26) | 0.271 |
| C | 1.0 (/) | 52.4 (3.20–859) | 0.005 | |
| Baseline AFP | ||||
| < 200 | 17.0 (9.3–24.6) | 0.003 | 1.00 (0.8–1.2) | 0.278 |
| ≥ 200 | 6.7 (5.6–7.8) | |||
| Prior locoregional treatment | ||||
| Yes | 24.0 (20.1–27.9) | <0.0001 | 1.00 | |
| No | 7.3 (5.0–9.5) | 2.30 (1.37–3.86) | 0.002 | |
| Liver disease aetiology | ||||
| Alcoholic | 8.6 (3.80–13.3) | 0.192 | ||
| Other | 16.7 (13.5–19.9) | |||
| BCLC stage | ||||
| A | 22.4 (7.0–37.7) | |||
| B | 14.5 (5.1–23.9) | 0.539 | ||
| C | 13.4 (7.1–19.7) | |||
| Gender | ||||
| Female | 8.8 (7.0–10.7) | 0.944 | ||
| Male | 13.8 (10.1–17.6) | |||
| Age | ||||
| < 70 years | 15.0 (11.2–18.8) | 0.201 | ||
| ≥ 70 years | 8.4 (6.0–10.8) | |||